FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileClinuvel Pharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CUV.AX
Clinuvel Pharmaceuticals Limited Stock AnalysisComprehensive stock analysis for Clinuvel Pharmaceuticals Limited (CUV.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCUV.AX
CUV.AX
Clinuvel Pharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CUV.AX
  1. Home
  2. Stocks
  3. Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited

🇦🇺CUV.AX•ASX

Clinuvel Pharmaceuticals Limited

🇦🇺CUV.AX•ASX
P/E ratio
10.72

Your view on CUV.AX

P/E
10.72
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Clinuvel Pharmaceuticals Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Philippe Jacques Wolgen
Headquarters
535 Bourke Street, Melbourne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Philippe Jacques Wolgen
Headquarters
535 Bourke Street, Melbourne, VIC, AU
Description

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets.

The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP).

Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.

Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Clinuvel Pharmaceuticals Limited from FRC's valuation model, read against the market price. CUV.AX last traded at AUD 9.44, 10.7× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Clinuvel Pharmaceuticals Limited. Starting points for Clinuvel Pharmaceuticals Limited: P/E 10.7, EPS AUD 0.68, beta 0.61 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Clinuvel Pharmaceuticals Limited. Clinuvel Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Clinuvel Pharmaceuticals Limited. Trailing twelve-month EPS for Clinuvel Pharmaceuticals Limited stands at AUD 0.68. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis quarterJun 2018Next quarterJun 2019This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 0.48AUD 0.47AUD 0.67AUD 0.69
Lowest estimateAUD 0.47AUD 0.34AUD 0.61AUD 0.52
Highest estimateAUD 0.50AUD 0.62AUD 0.80AUD 0.98
Number of analysts2355
A year ago——AUD 0.68—
Growth vs a year ago——−1.8%—

Revenue estimates

TotalThis quarterJun 2018Next quarterJun 2019This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 46.99MAUD 41.87MAUD 93.17MAUD 98.61M
Lowest estimateAUD 44.91MAUD 30.07MAUD 88.57MAUD 84.48M
Highest estimateAUD 47.23MAUD 52.54MAUD 97.37MAUD 121.71M
Number of analysts2366
A year ago——AUD 94.02M—
Growth vs a year ago——−0.9%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Clinuvel Pharmaceuticals Limited. Clinuvel Pharmaceuticals Limited has reported as a listed company since 2001. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CUV.AX13 companies · 8 funds
Compare CUV.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
BOT.AXBotanix Pharmaceuticals LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PHRRFPharmaTher Holdings Ltd.HealthcareOTC$5.3M
PHVSPharvaris N.V.HealthcareNASDAQ$2.2B
PHYOFIXICO plcHealthcareOTC$6.5M
PKTXProtoKinetix, IncorporatedHealthcareOTC$2.7M
PLRXPliant Therapeutics, Inc.HealthcareNASDAQ$41.0M
PLRZPolyrizon Ltd.HealthcareNASDAQ$12.4M
PLURPluri Inc.HealthcareNASDAQ$9.9M
PLXProtalix BioTherapeutics, Inc.HealthcareAMEX$254.6M
PLYXPolaryx Therapeutics, Inc. Common StockHealthcareNASDAQ$80.3M
PMCBPharmaCyte Biotech, Inc.HealthcareNASDAQ$3.0M
PMNProMIS Neurosciences, Inc.HealthcareNASDAQ$28.2M
PMVPPMV Pharmaceuticals, Inc.HealthcareNASDAQ$65.1M
ETFs holding Clinuvel Pharmaceuticals Limited
TickerFundFund assets% of the fund
VXUSVanguard Total International Stock ETF$163.2B in assets0.00%
VEAVanguard FTSE Developed Markets ETF$231.6B in assets0.00%
VSSVanguard FTSE All-World ex-US Small-Cap ETF$11.6B in assets0.01%
SCHCSchwab International Small-Cap Equity ETF$5.4B in assets0.01%
GWXState Street SPDR S&P International Small Cap ETF$882M in assets0.02%
ISCFiShares International Small-Cap Equity Factor ETF$717M in assets0.01%
AVDSAvantis International Small Cap Equity ETF$379M in assets0.01%
DISVDimensional - International Small Cap Value ETF$5.1B in assets0.00%

Largest holders first, then the funds most concentrated in CUV.AX.

Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Clinuvel Pharmaceuticals Limited. Coverage tracks Clinuvel Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Clinuvel Pharmaceuticals Limited.

CUV.AX AnalysisGood
Past
1
Growth
3
Health
5
Profit
3
Value
3